Abstract
Widening indications for combining radiation therapy with cytotoxic or molecular-targeted drugs have mainly been driven by pragmatic clinical trials. With a flurry of novel drugs in various stages of preclinical and clinical development there is a need to revise the framework that has traditionally been used for discussing possible drug–radiation interactions, especially because many of the new drugs are directed at a specific molecular target. Spatial cooperation, cytotoxic enhancement, biological cooperation, temporal modulation and normal tissue protection are proposed as five primary exploitable mechanisms for the rational combination of drugs with radiation for cancer therapy. These five mechanisms produce different clinical outcomes and, therefore, the optimum clinical end point for assessing therapeutic benefit will depend on the mechanism tested. The dependence of outcome on these mechanisms also affects the selection of preclinical models and the optimum scheduling of the two modalities, i.e. the timing and dosing of the drug relative to the radiation dose fractions. These considerations are discussed in some detail for each mechanism and illustrated with specific clinical examples. Multi-modality therapy for head and neck squamous-cell carcinoma is used to illustrate these concepts. Further clinical progress in this field will require hypothesis-driven trials to ensure efficient identification of treatments with the most favorable risk:benefit ratio.
Key Points
-
The classical framework for discussing exploitable mechanisms for combining drugs and radiation was proposed by Peckham and Steel in 1979 and reflected the predominant focus on in vitro cytotoxicity
-
We propose a new conceptual framework consisting of five exploitable mechanisms: spatial cooperation, cytotoxic enhancement, biological cooperation, temporal modulation and normal tissue protection
-
Depending on the proposed mechanism, various preclinical models, clinical end points and dose-timing considerations may be optimum
-
Clinical indications for combining drugs with radiation therapy are widening, and clinical and preclinical research on combined modality therapy will intensify in the next few years
-
Optimum use of drug–radiation combinations will require individualized risk profiling to identify the potential clinical resistance issues and the predicted pattern of failure in a specific patient
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jaffe N et al. (1976) Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38: 1925–1930
Hustu HO et al. (1968) Treatment of Ewing's sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr 73: 249–251
Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85–91
Bernier J (2005) Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat Clin Pract Oncol 2: 305–314
Ma BB et al. (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21: 2760–2776
Wilson GD et al. (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16: 2–9
Bentzen SM et al. (1989) Early and late normal-tissue injury after postmastectomy radiotherapy alone or combined with chemotherapy. Int J Radiat Biol 56: 711–715
Denis F et al. (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55: 93–98
Trotti A and Bentzen SM (2004) The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22: 19–22
Bernier J and Bentzen SM (2003) Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 39: 560–571
Kim JJ and Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516–525
Bentzen SM (2003) Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79: 581–585
De Ruysscher D et al. (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24: 1057–1063
Whelan TJ (2005) Use of conventional radiation therapy as part of breast-conserving treatment. J Clin Oncol 23: 1718–1725
Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106
Schild SE et al. (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59: 943–951
Turrisi AT III et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340: 265–271
Aviles A et al. (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45: 1385–1389
Dieckmann K et al. (2003) Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German–Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys 56: 644–652
van Rijn J et al. (2000) Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47: 779–784
Chinnaiyan P et al. (2006) Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 16: 59–64
Munshi A et al. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912–4922
Brunner TB et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 65: 8433–8441
Erjala K et al. (2004) Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro. Acta Oncol 43: 169–174
Wong M et al. (2006) Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 24: 2448–2455
Edelstein MP et al. (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23 (Suppl 5): S41–S47
Zhang M et al. (2004) Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 58: 353–360
Nishimura Y (2004) Rationale for chemoradiotherapy. Int J Clin Oncol 9: 414–420
Brunner TB et al. (2003) Farnesyltransferase inhibitors as radiation sensitizers. Int J Radiat Biol 79: 569–576
Dey S et al. (2003) Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 9: 1557–1565
Peters KB and Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62: 5248–5253
Tozer GM and Bicknell R (2004) Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 14: 222–232
Tozer GM et al. (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423–435
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62
Withers HR (1975) The four R's of radiotherapy. Adv Radiat Biol 5: 241–247
Harari PM and Huang SM (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49: 427–433
Milas L et al. (2003) Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park) 17 (Suppl 5): S15–S24
Bentzen SM (2006) Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6: 702–713
Trotti A (1998) Toxicity antagonists in head and neck cancer. Semin Radiat Oncol 8: 282–291
Spielberger R et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351: 2590–2598
Movsas B et al. (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23: 2145–2154
Brizel DM et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339–3345
Bentzen SM et al. (2003) Normal tissue effects: reporting and analysis. Semin Radiat Oncol 13: 189–202
Green J et al. (2005) Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane Database Systematic Reviews, Issue 3, Art. No CD002225.
Trotti A (2000) Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47: 1–12
Bieri S et al. (2003) Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer: experience from four nonrandomized studies. Strahlenther Onkol 179: 390–395
Bentzen SM and Bernier J (2002) Chemotherapy and altered fractionation in head-and-neck cancer: in regard to Staar et al., IJROBP 2001; 50: 1161–1171. Int J Radiat Oncol Biol Phys 52: 1423–1424
Cooper JS and Ang KK (2005) Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys 61: 7–9
Eng C et al. (2004) Chemotherapy and radiation of anal canal cancer: the first approach. Surg Oncol Clin N Am 13: 309–320, viii.
UKCCCR Anal Cancer Trial Working Party; UK Co-ordinating Committee on Cancer Research (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348: 1049–1054
Bosset JF et al. (1997) Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups. Lancet 349: 205–206
Flam M et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14: 2527–2539
Thomas GM (2000) Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. Semin Radiat Oncol 10: 44–50
Lukka H et al. (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis. Clin Oncol (R Coll Radiol) 14: 203–212
Zatloukal P et al. (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87–98
Vokes EE et al. (2005) Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 11 (Suppl 2): S5045–S5050
Browman GP et al. (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23: 579–589
Bernier J and Bourhis J (2005) Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment. Ann Oncol 16: 1722
Cooper JS et al. (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937–1944
Bernier J et al. (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945–1952
Wadsley JC and Bentzen SM (2004) Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 60: 1405–1409
Bonner JA et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578
Bentzen SM et al. (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560–5567
Koukourakis MI et al. (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727–735
Nordsmark M et al. (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol 77: 18–24
Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38–47
Forastiere AA et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091–2098
Remenar E et al. (2006) A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): final analysis of EORTC 24971 [abstract]. J Clin Oncol 24: 5516
Dunne AL et al. (2004) Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res 14: 447–454
Ataman OU et al. (2004) Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 40: 2734–2741
Belbin TJ et al. (2002) Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62: 1184–1190
Buffa FM et al. (2004) Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10: 3745–3754
Chung CH et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489–500
Salesiotis AN and Cullen KJ (2000) Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 12: 229–239
Bentzen SM (2005) Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 77: 227–230
Moran JM et al. (2005) Radiotherapy: what can be achieved by technical improvements in dose delivery? Lancet Oncol 6: 51–58
Bentzen SM (2005) Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6: 112–117
Stupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996
Schaake-Koning C et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524–530
Rischin D et al. (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24: 2098–2104
Bentzen SM (2003) A user's guide to evidence-based oncology. Eur J Cancer Suppl 6: S77–S91
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SM Bentzen has received an honorarium from ImClone. PM Harari holds research and consulting agreements with Amgen, AstraZeneca, Genentech and ImClone. J Bernier declared he has no competing interests.
Rights and permissions
About this article
Cite this article
Bentzen, S., Harari, P. & Bernier, J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Rev Clin Oncol 4, 172–180 (2007). https://doi.org/10.1038/ncponc0744
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0744
This article is cited by
-
Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy
Strahlentherapie und Onkologie (2023)
-
Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure
BMC Cancer (2022)
-
Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Current Treatment Options in Oncology (2022)
-
Radio-selective effects of a natural occurring muscle-derived dipeptide in A549 and normal cell lines
Scientific Reports (2019)